Get started
Author

Tetsu Tomonari

Observed names: T., Tomonari, TETSU TOMONARI, Tomonari Tetsu, Tomonari, T., Tomonari, Tetsu
Observed institution: Tokushima University
ORCID: 0000-0002-8484-9866
Observed ORCID: 0000-0002-8484-9866
OpenAlex ID: A5037589463
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
2023 · Masatoshi Kudo, Tomoko Aoki, et al. · Liver Cancer · 161
PDF
Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients
2019 · Masaki Maeda, Issei Saeki, et al. · Liver Cancer · 77
MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma
2016 · Tetsu Tomonari, Shunsaku Takeishi, et al. · Oncotarget · 66
PDF
Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs
2015 · Jinsei Miyoshi, Hiroshi Miyamoto, et al. · Journal of Gastroenterology and Hepatology · 60
Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib
2020 · Tetsu Tomonari, Yasushi Sato, et al. · Medicine · 47
MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
2021 · Akihiro Hirao, Yasushi Sato, et al. · Cancers · 32
PDF
Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
2023 · Tetsu Tomonari, Joji Tani, et al. · Cancers · 27
PDF
Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular‐targeted agent sequential therapy: A propensity score‐matched analysis
2020 · Tetsu Tomonari, Yasushi Sato, et al. · Hepatology Research · 27
Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array
2020 · Tetsu Tomonari, Yasushi Sato, et al. · Oncotarget · 24
PDF
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice
2024 · Shigeo Shimose, Issei Saeki, et al. · Oncology Letters · 22
PDF
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
2022 · Tetsu Tomonari, Joji Tani, et al. · Cancer Medicine · 22
Novel des‐γ‐carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma
2013 · Takahiro Tanaka, Tatsuya Taniguchi, et al. · Journal of Gastroenterology and Hepatology · 22
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy
2024 · Issei Saeki, Shigeo Shimose, et al. · PLoS ONE · 20
PDF
Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome
2020 · Masahiro Sogabe, Toshiya Okahisa, et al. · PLoS ONE · 19
PDF
Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
2020 · Tetsu Tomonari, Yasushi Sato, et al. · JGH Open · 19
PDF
Light alcohol consumption plays a protective role against non‐alcoholic fatty liver disease in Japanese men with metabolic syndrome
2014 · Masahiro Sogabe, Toshiya Okahisa, et al. · Liver International · 19
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study
2025 · Tomoko Aoki, Masatoshi Kudo, et al. · Journal of Gastroenterology · 18
PDF
APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism
2018 · Rie Harada, Masako Kimura, et al. · BMC Gastroenterology · 16
PDF
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
2021 · Tetsu Tomonari, Yasushi Sato, et al. · JGH Open · 15
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma
2022 · Tetsu Tomonari, Joji Tani, et al. · Hepatology Research · 13
Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis
2021 · Hironori Ochi, Joji Tani, et al. · Hepatology Research · 12
Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome
2016 · Masahiro Sogabe, Toshiya Okahisa, et al. · BMC Gastroenterology · 12
PDF
Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma
2021 · Takeshi Imakura, Seidai Sato, et al. · Internal Medicine · 11
PDF
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
2025 · Shigeo Shimose, Issei Saeki, et al. · Hepatology International · 10
Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study
2023 · Masahiro Sogabe, Toshiya Okahisa, et al. · Clinical Nutrition · 10
PDF
Works count: 99
Citation count: 915
H-index: 17
I10-index: 27
Year
Topic
Type